• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • What information needs to be provided when applying for a change in the packaging specifications of in vitro diagnostic reagents?

What information needs to be provided when applying for a change in the packaging specifications of in vitro diagnostic reagents?

Friday, 23 April 2021 / Published in Medical Device, News, NMPA Registration in China

What information needs to be provided when applying for a change in the packaging specifications of in vitro diagnostic reagents?

According to the announcement published by the CMDE (Centre for Medical Device Evaluation) of the National Medical Products Administration (NMPA) on April 12, 2021, all relevant potential risks should be identified when the packaging specifications of IVD reagents are being changed. In addition, the risk factors should be analyzed and validated.

Case Study I

If there are differences in the form of the reaction (e.g. drug assays) and the size of the reaction film strip (e.g. PCR amplification and hybridisation products), the assessment of the analytical performance should be submitted.

Case Study II

If significant changes in packaging specifications and containers have led to risks such as evaporation and loss, it is necessary to study and investigate whether the shelf life of the product, the stability of use, and the frequency of calibration is no longer the same.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: In vitro diagnostics, IVD reagents, packaging

What you can read next

ICH E8 (R1)
ICH E8 (R1) General Considerations for Clinical Studies have been approved in China
Clinical Trials GMP management
Medical device clinical trial data submission – New registration requirements issued
New Details on Sampling Inspections of Medical Devices

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Physicochemical characterization of nanomaterials

    Physicochemical characterization of nanomaterials used in medical devices – New guidelines issued

    Physicochemical characterization of nanomateria...
  • Registration of disposable light-proof infusion sets in China

    Registration of disposable light-proof infusion sets in China – Amended guidelines issued

    Registration of disposable light-proof infusion...
  • Registration of disposable blood separation devices in China

    Registration of disposable blood separation devices in China – Amended guidelines issued

    Registration of disposable blood separation dev...
  • Registration of disposable infusion devices in China

    Registration of disposable infusion devices in China – Amended guidelines issued

    Registration of disposable infusion devices in ...
  • Registration of blood dialyzers in China

    Registration of blood dialyzers in China – Amended guidelines issued

    Registration of blood dialyzers in China shall ...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP